CardioWise Software Used In Clinical Trials at National Institutes of Health
by February 2, 2015 12:00 am 111 views
CardioWise Inc., a portfolio company for Fayetteville-based VIC Technology Venture Development LLC, recently installed its analysis software to be used in clinical trials at the National Institutes of Health.
During the clinical trials, the technology — the installation of which was completed Feb. 2 — will be used to gauge effectiveness of stem cell injection into damaged heart muscle for open-heart surgery patients participating in research at the National Heart, Lung and Blood Institute in Bethesda, Maryland.
The analysis software is unique because it uses an algorithm to create a 3-D (4-D if you consider it also takes time into account) image of the heart and draws upon a database that enables it to normalize the results.
The result is in a user-friendly form, an image that is color-coded blue for normal, yellow for not normal and red for at-risk, Coats said.
Coats said CardioWise is ideal for clinical trials, as it takes subjectivity out of the diagnosis, gauging the health of the heart function based on quantitative data.
If CardioWise earns clearance from the Food and Drug Administration, which Coats expects to gain in a little over a year, the company will open an office in Fayetteville, employing marketing professionals and developers.
Local board members for CardioWise include chairman Omid Moghadam, CEO of Ascendant Dx; Calvin Goforth, CEO of VIC Technology; and Jeff Amerine, principal of Startup Junkie Consulting LLC.